JP2008503595A - テルミサルタンの調製方法 - Google Patents
テルミサルタンの調製方法 Download PDFInfo
- Publication number
- JP2008503595A JP2008503595A JP2007518396A JP2007518396A JP2008503595A JP 2008503595 A JP2008503595 A JP 2008503595A JP 2007518396 A JP2007518396 A JP 2007518396A JP 2007518396 A JP2007518396 A JP 2007518396A JP 2008503595 A JP2008503595 A JP 2008503595A
- Authority
- JP
- Japan
- Prior art keywords
- telmisartan
- formula
- acid
- bim
- alkyl ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title claims abstract description 156
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title claims abstract description 92
- 229960005187 telmisartan Drugs 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims description 25
- 238000000034 method Methods 0.000 claims abstract description 74
- 238000006243 chemical reaction Methods 0.000 claims abstract description 16
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 23
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical group CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 21
- 239000012074 organic phase Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 150000007529 inorganic bases Chemical class 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 15
- 238000009835 boiling Methods 0.000 claims description 12
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 claims description 12
- 125000005907 alkyl ester group Chemical group 0.000 claims description 11
- 150000002576 ketones Chemical class 0.000 claims description 11
- 150000004100 telmisartan derivatives Chemical class 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 5
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 5
- 150000004692 metal hydroxides Chemical class 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 4
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 claims description 4
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 4
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical group CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 4
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 235000011181 potassium carbonates Nutrition 0.000 claims description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 150000003983 crown ethers Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 125000003944 tolyl group Chemical group 0.000 claims description 3
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 150000004714 phosphonium salts Chemical class 0.000 claims description 2
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 claims description 2
- 229910001866 strontium hydroxide Inorganic materials 0.000 claims description 2
- BGQMOFGZRJUORO-UHFFFAOYSA-M tetrapropylammonium bromide Chemical compound [Br-].CCC[N+](CCC)(CCC)CCC BGQMOFGZRJUORO-UHFFFAOYSA-M 0.000 claims description 2
- IPILPUZVTYHGIL-UHFFFAOYSA-M tributyl(methyl)azanium;chloride Chemical compound [Cl-].CCCC[N+](C)(CCCC)CCCC IPILPUZVTYHGIL-UHFFFAOYSA-M 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 abstract description 23
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 19
- 238000010992 reflux Methods 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- -1 HCl Chemical class 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 5
- HJCCZIABCSDUPE-UHFFFAOYSA-N methyl 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoate Chemical group CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC HJCCZIABCSDUPE-UHFFFAOYSA-N 0.000 description 5
- 239000003444 phase transfer catalyst Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 238000003828 vacuum filtration Methods 0.000 description 5
- QQHZAARABFGGBY-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=C(CBr)C=C1 QQHZAARABFGGBY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000013067 intermediate product Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- TWJLAXZTCOOIOH-UHFFFAOYSA-N CCCc([n](Cc(cc1)ccc1-c(cccc1)c1C(O)=O)c1c2)nc1c(C)cc2-c1nc(C=CCC2)c2[n]1C Chemical compound CCCc([n](Cc(cc1)ccc1-c(cccc1)c1C(O)=O)c1c2)nc1c(C)cc2-c1nc(C=CCC2)c2[n]1C TWJLAXZTCOOIOH-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 1
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001466453 Laminaria Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- DKEONVNYXODZRQ-UHFFFAOYSA-N hydron;2-n-methylbenzene-1,2-diamine;dichloride Chemical compound Cl.Cl.CNC1=CC=CC=C1N DKEONVNYXODZRQ-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- RMXGTMRDXKUUDJ-UHFFFAOYSA-N methyl 2-[4-(bromomethyl)phenyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(CBr)C=C1 RMXGTMRDXKUUDJ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- OWQCENTZHZJGTR-UHFFFAOYSA-N tert-butyl 2-phenylbenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1C1=CC=CC=C1 OWQCENTZHZJGTR-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
ある観点において、本発明は、式II
(a)混合物を得るために、式III
(b)工程(a)において得られた混合物を約55℃〜約120℃の温度に加熱する工程;
(c)式IIのテルミサルタンアルキルエステルを得るために、工程(b)において得られた混合物を約1時間〜約8時間維持する工程;及び
(d)式IIのテルミサルタンアルキルエステル(式中、Rは直鎖又は分枝鎖C1-4アルキルである)を回収する工程、
を含んで成る方法を供する。
(a)混合物を得るために、式IIIのBIM、式IVのBMBPアルキルエステル、無機塩基、及びケトン溶媒を混合する工程;
(b)工程(a)において得られた混合物を約55℃〜約120℃の温度に加熱する工程;
(c)式V
(d)水相から式Vのテルミサルタン塩を含む有機相を分離する工程;
(e)式Vのテルミサルタン塩を式Iのテルミサルタンに変換する工程;及び
(f)式Iのテルミサルタン
(式中、
Rは直鎖又は分枝鎖C1-4アルキルであり、そして
Mは金属原子である)を回収する工程、
を含んで成る方法を供する。
本明細書において使用される「低沸点」の語は、約55℃〜約120℃の沸点を意味する。
(a)混合物を得るために、式III
(b)工程(a)において得られた混合物を約55℃〜約120℃の温度に加熱する工程;
(c)式IIのテルミサルタンアルキルエステルを得るために、工程(b)において得られた混合物を約1時間〜約8時間維持する工程;及び
(d)式IIのテルミサルタンアルキルエステル(式中、Rは直鎖又は分枝鎖C1-4アルキルである)を回収する工程、
を含んで成る方法を供する。
(a)混合物を得るために、式IIIのBIM、式IVのBMBPアルキルエステル、無機塩基、及びケトン溶媒を混合する工程;
(b)工程(a)において得られた混合物を約55℃〜約120℃の温度に加熱する工程;
(c)式V
(d)水相から式Vのテルミサルタン塩を含む有機相を分離する工程;
(e)式Vのテルミサルタン塩を式Iのテルミサルタンに変換する工程;及び
(f)式Iのテルミサルタン
(式中、
Rは直鎖又は分枝鎖C1-4アルキルであり、そして
Mは金属原子である)を回収する工程、
を含んで成る方法を供する。
1,7’−ジメチル−2’−プロピル−1H,3’H−[2,5’]ビベンゾイミダゾリル(BIM)(4g)、Aliquat(登録商標)175(1.36ml)、K2CO3(8.19g)、及びトルエン(50ml)をマグネチック撹拌子と還流冷却器を備える250mlの丸底フラスコに添加した。透明な褐色の有機溶液が得られるまで当該混合物を還流温度(約85〜90℃)に加熱した。反応混合物を形成するためにトルエン(24ml)中の4’ブロモメチル−ビフェニル−2−カルボン酸(BMBP)メチルエチルエステル(4.5g)を当該透明な褐色の有機溶液に添加した。当該反応混合物を約6時間撹拌し、それから氷浴により冷却し、そして濾過し、冷却された反応混合物を形成した。それから冷却反応混合物を水(20ml)で2回抽出し、MgSO4で乾燥させ、そして蒸発させ、約69%の収率であるテルミサルタンメチルエステル(5.02g)を形成した。
1,7’−ジメチル−2’−プロピル−1H,3’H−[2,5’]ビベンゾイミダゾリル(BIM)(4g)、NaOH(15mlの水中4.26g)、及びメチルエチルケトン(40ml)を、マグネチック撹拌子と還流冷却器を備える250mlの丸底フラスコに添加し、混合物を形成した。透明なBIM溶液が得られるまで当該混合物を還流温度に加熱した。メチルエチルケトン(16ml)中の4’−ブロモメチル−ビフェニル−2−カルボン酸(BMBP)メチルエチルエステル(4.5g)を透明なBIM溶液に添加し、反応混合物を形成した。当該反応混合物を約2時間撹拌し、それから室温に冷却した。それから冷却反応混合物を水(15ml)で抽出し、MgSO4で乾燥させ、そして蒸発させ、約79%の収率であるテルミサルタンメチルエステル(5.76g)を得た。
1,7’−ジメチル−2’−プロピル−1H,3’H−[2,5’]ビベンゾイミダゾリル(BIM)(4g)、硫酸水素テトラブチルアンモニウム(TBAHS)(0.45g)及びNaOH(1.05g)、水(15ml)、並びにトルエン(40ml)を、マグネチック撹拌子と還流冷却器を備える250mlの丸底フラスコに添加し、BIM混合物を形成した。当該BIM混合物を還流温度(80〜90℃)で加熱した。トルエン(16ml)中の4’ブロモメチル−ビフェニル−2−カルボン酸(BMBP)メチルエチルエステル(4.5g)を、温かいBIM溶液に添加し、反応混合物を形成し、そして当該反応混合物を3.5時間撹拌し、それから室温に冷却した。それから冷却反応混合物を水(15ml)で抽出し、水相と有機相を形成した。当該有機相をMgSO4で乾燥させ、それから蒸発させ、約100%の収率であるテルミサルタンメチルエステル(7.41g)を得た。
1,7’−ジメチル−2’−プロピル−1H,3’H−[2,5’]ビベンゾイミダゾリル(BIM)(4g)、Aliquat(登録商標)175(0.47ml)、NaOH(4.85g)、水(16ml)、及び酢酸イソブチル(40ml)をマグネチック撹拌子と還流冷却器を備える250mlの丸底フラスコに添加し、そして還流温度(約80℃)で加熱して、温かいBIM混合物を形成した。酢酸イソブチル(16ml)中の4’−ブロモメチル−ビフェニル−2−カルボン酸(BMBP)メチルエステル(4.5g)を温かいBIM混合物に添加し、反応混合物を形成し、そして当該反応混合物を約1時間撹拌し、それから室温に冷却した。それから水(20ml)で冷却反応混合物を抽出し、水相と有機相を形成した。当該有機相をMgSO4で乾燥させ、そして蒸発させ、約76%の収率であるテルミサルタンメチルエステル(5.56g)を形成した。
250mlの丸底フラスコにBIM(4g)、メチルエチルケトン(40ml)、及び水性NaOH(22%又は19.26グラム)を充填し、BIM混合物を形成した。当該BIM混合物を80℃に加熱し、そしてメチルエチルケトン(16ml)中のBMBPメチルエステル(4g)の溶液をBIM混合物に添加し、反応混合物を形成した。当該反応混合物を約24時間撹拌し、有機相と水相を形成した。当該2つの相を分離し、そして有機相を2つに分けた。約1mlの氷酢酸を2つのうちの一方にpHが約4.7に調整されるまで添加し、数分後に沈殿を伴う溶液を形成した。当該溶液を室温で一晩撹拌し、生成物を形成した。当該生成物を減圧濾過により単離し、そして真空オーブン中50℃で24時間乾燥させ、2.7g又は80%の収率のテルミサルタンを得た。
250mlの丸底フラスコにBIM(8g)、アセトン(96ml)、及びNaOH水溶液(35%、20ml)を充填し、BIM混合物を形成し、これを還流温度で加熱した。アセトン(32ml)中のBMBPメチルエステル(8g)を温かいBIM混合物に添加し、反応混合物を形成した。当該反応混合物を約24時間撹拌し、有機相と水相を形成した。当該相を分離し、そして有機相を2つに分けた。最初の有機部分(48ml)を還流温度に加熱し、そして氷酢酸(1ml)を添加し、pHを5.5に調整した。最初の有機部分を室温に冷却し、そして一晩撹拌し、沈殿物を形成した。当該沈殿物を減圧濾過により単離し、アセトン(40ml)で洗浄し、そして真空オーブン中50℃で24時間乾燥させ、6.58gのテルミサルタンを得た(収率79%)。
100mlの反応容器にBIM(4g)、メチルイソブチルケトン(48ml)、及びNaOH水溶液(35%、10ml)を充填し、BIM混合物を形成した。当該BIM混合物を78℃に加熱し、そしてメチルイソブチルケトン(16ml)中のBMBPメチルエステル(4g)の溶液を加温されたBIM混合物に添加し、反応混合物を形成した。当該反応混合物を還流温度で約24時間撹拌し、有機相と水相を伴う反応混合物を形成した。当該相を分離し、そして氷酢酸(2ml)を有機相に添加した。2時間後、反応混合物を室温に冷却し、そして3時間撹拌し、テルミサルタン沈殿物を形成した。当該テルミサルタン沈殿物を減圧濾過により単離し、エタノール(40ml)で洗浄し、そして真空オーブン中50℃で24時間乾燥させ、4.59gのテルミサルタンを得た(収率68%)。
Claims (30)
- 式II
(a)混合物を得るために、式III
(b)工程(a)において得られた混合物を約55℃〜約120℃の温度に加熱する工程;
(c)式IIのテルミサルタンアルキルエステルを得るために、工程(b)において得られた混合物を約1時間〜約8時間維持する工程;及び
(d)式IIのテルミサルタンアルキルエステル(式中、Rは直鎖又は分枝鎖C1-4アルキルである)を回収する工程、
を含んで成る方法。 - 単一の反応容器における、テルミサルタンの調製のための方法であって、以下の工程
(a)混合物を得るために、式IIIのBIM、式IVのBMBPアルキルエステル、無機塩基、及びケトン溶媒を混合する工程;
(b)工程(a)において得られた混合物を約55℃〜約120℃の温度に加熱する工程;
(c)式V
(d)水相から式Vのテルミサルタン塩を含む有機相を分離する工程;
(e)式Vのテルミサルタン塩を式Iのテルミサルタンに変換する工程;及び
(f)式Iのテルミサルタン
(式中、
Rは直鎖又は分枝鎖C1-4アルキルであり、そして
Mは金属カチオンである)を回収する工程、
を含んで成る方法。 - 前記直鎖又は分枝鎖C1-4アルキルがメチルである、請求項1又は2に記載の方法。
- 前記低沸点溶媒が、C6-10芳香族炭化水素、ケトン、エステル、及びこれらの混合物から成る群から選択される、請求項1に記載の方法。
- 工程(a)において、水を低沸点溶媒に添加することができる、請求項1に記載の方法。
- 工程(a)において、水をケトン溶媒に添加することができる、請求項2に記載の方法。
- 前記C6-10芳香族炭化水素がトルエンである、請求項4に記載の方法。
- 前記ケトンがメチルエチルケトン、メチルイソブチルケトン、又はアセトンである、請求項2又は4に記載の方法。
- 前記エステルが酢酸イソブチルである、請求項4に記載の方法。
- 前記低沸点有機溶媒がトルエンである、請求項4に記載の方法。
- 前記ケトンがアセトンである、請求項7に記載の方法。
- 工程(a)において使用されるBIMの量がモル当量のBMBPあたり約0.8〜約1.5モル当量である、請求項1又は2に記載の方法。
- 工程(a)において使用されるBIMの量がモル当量のBMBPあたり約0.9〜約1モル当量である、請求項12に記載の方法。
- 前記無機塩基が、金属水酸化物、及び金属炭酸塩から成る群から選択される、請求項1又は2に記載の方法。
- 前記金属水酸化物が、水酸化ナトリウム、水酸化カリウム、水酸化セシウム、水酸化バリウム、水酸化マグネシウム、水酸化カルシウム、又は水酸化ストロンチウムである、請求項14に記載の方法。
- 前記金属炭酸塩が、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、炭酸水素カリウム、又は炭酸セシウムである、請求項14に記載の方法。
- 前記無機塩基が、炭酸カリウム、又は水酸化ナトリウムのいずれかである、請求項14に記載の方法。
- 工程(a)において無機塩基の水溶液が使用される、請求項1又は2に記載の方法。
- 工程(a)においてPTCが使用される、請求項1に記載の方法。
- 前記PTCが、第四級アンモニウム化合物、クラウンエーテル、及びホスホニウム化合物から成る群から選択される、請求項19に記載の方法。
- 前記第四級アンモニウム化合物が、塩化トリブチルメチルアンモニウム(Aliquat(登録商標)175)、臭化テトラブチルアンモニウム(TBAB)、硫酸水素テトラブチルアンモニウム(TBAHS)、塩化ベンジルトリエチルアンモニウム、及び臭化テトラプロピルアンモニウム(TPAB)から成る群から選択される、請求項20に記載の方法。
- 工程(c)の温度が約78℃〜約120℃である、請求項1又は2に記載の方法。
- 工程(d)において得られた有機相に酸を添加することにより、式Vのテルミサルタン塩がテルミサルタンに変換される、請求項2に記載の方法。
- 約6以下のpHを得るために酸が添加される、請求項23に記載の方法。
- 約4〜約6のpHを得るために酸が添加される、請求項24に記載の方法。
- 前記酸が、トリフルオロ酢酸、硫酸、及び酢酸から成る群から選択される、請求項23に記載の方法。
- 前記酸が酢酸である、請求項26に記載の方法。
- 請求項1又は2に記載の方法に従い調製された式Iのテルミサルタン及び医薬的に許容される賦形剤を含んで成る医薬組成物。
- 請求項1又は2に記載の方法に従い調製された式Iのテルミサルタン及び医薬的に許容される担体を混合することを含んで成る、医薬製剤を調製するための方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61956304P | 2004-10-15 | 2004-10-15 | |
PCT/US2005/037001 WO2006044648A1 (en) | 2004-10-15 | 2005-10-13 | Process for preparing telmisartan |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008503595A true JP2008503595A (ja) | 2008-02-07 |
Family
ID=35649417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007518396A Pending JP2008503595A (ja) | 2004-10-15 | 2005-10-13 | テルミサルタンの調製方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US7501448B2 (ja) |
EP (1) | EP1699765A1 (ja) |
JP (1) | JP2008503595A (ja) |
KR (2) | KR20070061583A (ja) |
CN (1) | CN101039917A (ja) |
CA (1) | CA2581723A1 (ja) |
IL (1) | IL182067A0 (ja) |
MX (1) | MX2007004426A (ja) |
WO (1) | WO2006044648A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011515374A (ja) * | 2008-03-20 | 2011-05-19 | レツク・フアーマシユーテイカルズ・デー・デー | アンギオテンシンiiアンタゴニストの合成における触媒カルボニル化 |
JP2011153080A (ja) * | 2010-01-26 | 2011-08-11 | Dnp Fine Chemicals Fukushima Co Ltd | テルミサルタンアルキルエステルの製造法 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007004426A (es) | 2004-10-15 | 2007-06-14 | Teva Pharma | Procesos para preparar telmisartan. |
JP2009530256A (ja) * | 2006-03-17 | 2009-08-27 | シプラ・リミテッド | 4−[1−(4−シアノフェニル)−1−(1,2,4−トリアゾール−1−イル)メチル]ベンゾニトリルおよび4−[1−(1h−1,2,4−トリアゾール−1−イル)メチレンベンゾニトリル中間体 |
US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
EP2377531A2 (en) * | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
CZ302272B6 (cs) * | 2007-07-09 | 2011-01-19 | Zentiva, A. S. | Zpusob výroby 4´-[[4-methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-karboxylové kyseliny (telmisartanu) |
EP2103609A1 (en) * | 2008-03-20 | 2009-09-23 | Lek Pharmaceuticals D.D. | Catalyzed carbonylation in the synthesis of angiotensin ii antagonists |
WO2009123483A1 (en) | 2008-03-31 | 2009-10-08 | Zaklady Farmaceutyczne Polpharma Sa | Process for preparation of telmisartan |
EP2149566A1 (en) | 2008-07-15 | 2010-02-03 | Chemo Ibérica, S.A. | A process for the preparation of telmisartan |
EP2305650A1 (en) | 2009-09-21 | 2011-04-06 | Chemo Ibérica, S.A. | Novel process for the preparation of telmisartan |
KR20110094751A (ko) * | 2010-02-17 | 2011-08-24 | 동화약품주식회사 | 텔미사탄의 개선된 제조방법 |
WO2012028925A2 (en) | 2010-09-03 | 2012-03-08 | Ogene Systems (I) Pvt Ltd | An improved process for the preparation of telmisartan |
WO2012055941A1 (en) | 2010-10-27 | 2012-05-03 | Krka,Tovarna Zdravil, D. D., Novo Mesto | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
ITMI20102416A1 (it) * | 2010-12-27 | 2012-06-28 | Chemelectiva S R L | Intermedio per la preparazione di un principio attivo e processo per la sua preparazione |
CN102267949A (zh) * | 2011-06-14 | 2011-12-07 | 张长利 | 替米沙坦制备新工艺 |
KR101607661B1 (ko) * | 2013-12-24 | 2016-03-31 | 주식회사 파마코스텍 | 텔미사르탄의 신규 제조 방법 |
WO2016089845A1 (en) * | 2014-12-01 | 2016-06-09 | Virginia Commonwealth University | A convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction |
CN104610161A (zh) * | 2015-01-05 | 2015-05-13 | 河南师范大学 | 一种替米沙坦的制备方法 |
KR20160112732A (ko) * | 2015-03-20 | 2016-09-28 | 크리스탈지노믹스(주) | 텔미사르탄 칼륨염을 포함하는 약제학적 조성물 및 그 제조방법 |
CN106008357A (zh) * | 2016-06-14 | 2016-10-12 | 浙江华海药业股份有限公司 | 一种替米沙坦的新杂质及其合成方法 |
WO2023158787A1 (en) * | 2022-02-17 | 2023-08-24 | Woolsey Pharmaceuticals, Inc. | Taste-masking oral formulations of fasudil |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04253966A (ja) * | 1990-07-23 | 1992-09-09 | Dr Karl Thomae Gmbh | ベンゾイミダゾール、これらの化合物を含む製薬組成物 |
JPH04346978A (ja) * | 1991-02-06 | 1992-12-02 | Dr Karl Thomae Gmbh | ベンズイミダゾール類及びこれらの化合物を含有する薬剤組成物 |
CN1344712A (zh) * | 2001-07-30 | 2002-04-17 | 中国科学院上海药物研究所 | 替米沙坦的合成新路线 |
WO2004087676A1 (de) * | 2003-03-31 | 2004-10-14 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von telmisartan |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
US5591762A (en) * | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
US5210211A (en) * | 1991-06-21 | 1993-05-11 | Warner-Lambert Company | 4-(1h-pyrrol-1-yl) imidazoles with angiotension ii antagonist activity |
US5312958A (en) * | 1992-01-31 | 1994-05-17 | Takeda Chemical Industries, Ltd. | Process for producing 4-bromomethylbiphenyl compounds |
US5380910A (en) * | 1992-04-28 | 1995-01-10 | Ihara Chemical Industry Co., Ltd. | Method for producing an asymmetric biaryl derivative |
CA2128014A1 (en) * | 1992-12-07 | 1994-06-23 | Toshikazu Shimizu | Process for the preparation of imidazopyridine derivatives and intermediates |
JPH06298684A (ja) | 1993-04-15 | 1994-10-25 | Sankyo Co Ltd | 新規な4−(2−置換)フェニルベンジルブロミド類の製造法 |
DE19607135C1 (de) * | 1996-02-26 | 1997-04-24 | Great Lakes Chem Konstanz Gmbh | Verfahren zur Herstellung von unsymmetrisch substituierten Biphenylen |
FR2753195B1 (fr) * | 1996-09-09 | 1998-11-27 | Sanofi Sa | Procede pour la preparation d'un cyanobiphenyle |
US5892094A (en) * | 1997-01-08 | 1999-04-06 | Sumika Fine Chemicals Co., Ltd. | Process for preparing 4'-methyl-2-cyanobiphenyl |
US5998652A (en) * | 1997-01-21 | 1999-12-07 | Sumika Fine Chemicals Co., Ltd. | Process for preparing 2-cyanobiphenyl compound |
US6194599B1 (en) * | 1997-04-08 | 2001-02-27 | Catalytica, Inc. | Process for preparing biaryl compounds |
US5922898A (en) * | 1997-04-08 | 1999-07-13 | Catalytica Pharmaceuticals, Inc. | Process for preparing biaryl compounds |
IT1291551B1 (it) * | 1997-04-11 | 1999-01-11 | Luso Farmaco Inst | Processo per la preparazione di composti 4-bromometil bifenilici |
WO1999025679A1 (fr) * | 1997-11-14 | 1999-05-27 | Sumika Fine Chemicals Co., Ltd. | PROCEDE DE PRODUCTION DE tert-BUTYL 4'-METHYL-2-BIPHENYLCARBOXYLATE |
FR2771090B1 (fr) * | 1997-11-17 | 2000-02-04 | Sanofi Sa | Procede de preparation de derives de bromomethyl-biphenyle |
DE19901921C2 (de) | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
US6358986B1 (en) * | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
US6369271B1 (en) * | 1999-02-26 | 2002-04-09 | Boehringer Ingelheim Pharma Kg | Process for preparing derivatives of biphenyl-2-carboxylic acid |
IT1311920B1 (it) * | 1999-04-13 | 2002-03-20 | Dinamite Dipharma S P A In For | Metodo per la sintesi di derivati dell'acido 2-(4-metilfenil) benzoico |
DE19917025A1 (de) * | 1999-04-15 | 2000-10-19 | Boehringer Ingelheim Pharma | Verfahren zur Seitenkettenbromierung von in 2'-Stellung substituierten 4-Methylbiphenyl-derivaten |
DE19917524C2 (de) | 1999-04-17 | 2001-09-20 | Boehringer Ingelheim Pharma | Verfahren zur Nitrierung von Anilinderivaten |
AR006063A4 (es) * | 1999-04-17 | 1999-08-11 | Romario S R L | Bandeja termica para pizzas |
CN1204124C (zh) | 2001-10-15 | 2005-06-01 | 中国科学院上海药物研究所 | 替米沙坦的一种制备路线 |
US6737432B2 (en) * | 2001-10-31 | 2004-05-18 | Boehringer Ingelheim Pharma Kg | Crystalline form of telmisartan sodium |
CZ303145B6 (cs) | 2002-01-16 | 2012-05-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Zpusob výroby dvojvrstevné farmaceutické tablety obsahující telmisartan a hydrochlorthiazid |
US6770762B2 (en) * | 2002-01-18 | 2004-08-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing and purifying 1,7′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole |
US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
DE10244681A1 (de) | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
US9029363B2 (en) * | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
CN1548421A (zh) | 2003-05-22 | 2004-11-24 | 上海医药工业研究院 | 替米沙坦盐及其制备方法 |
US7411082B2 (en) * | 2004-03-29 | 2008-08-12 | Cambridge University Technical Services Ltd. | Synthesizing method for compound, and catalyst for synthesis reaction |
DK1641438T3 (da) | 2004-06-01 | 2010-06-07 | Teva Gyogyszergyar Zartkoeruen | Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel |
MX2007004426A (es) | 2004-10-15 | 2007-06-14 | Teva Pharma | Procesos para preparar telmisartan. |
EP1805146A4 (en) * | 2004-10-18 | 2009-01-14 | Reddys Lab Ltd Dr | PROCESS FOR THE PREPARATION OF TELMISARTAN |
KR20070072588A (ko) | 2004-11-03 | 2007-07-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 텔미사르탄 나트륨의 비정질형 및 다형 |
US20060111417A1 (en) * | 2004-11-23 | 2006-05-25 | Purandhar Koilkonda | Amorphous telmisartan |
US20060211866A1 (en) * | 2005-03-21 | 2006-09-21 | Glenmark Pharmaceuticals Limited | Process for the preparation of angiotensin receptor blockers and intermediates thereof |
ITMI20050801A1 (it) * | 2005-05-03 | 2006-11-04 | Dipharma Spa | Procedimento per la preparazione di telmisartan |
IL175718A0 (en) * | 2005-05-18 | 2007-08-19 | Chemagis Ltd | Novel processes for preparing crystalline telmisartan form a by crystallization from dmf |
DE102005034279A1 (de) * | 2005-07-22 | 2007-01-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Herstellung von 1,7'-Dimethyl-2'-propyl-2,5'-bi-1H-benzimidazol |
US20060264491A1 (en) * | 2006-06-08 | 2006-11-23 | Chemagis Ltd. | Telmisartan production process |
-
2005
- 2005-10-13 MX MX2007004426A patent/MX2007004426A/es unknown
- 2005-10-13 WO PCT/US2005/037001 patent/WO2006044648A1/en active Application Filing
- 2005-10-13 CA CA002581723A patent/CA2581723A1/en not_active Abandoned
- 2005-10-13 KR KR1020077010244A patent/KR20070061583A/ko active Search and Examination
- 2005-10-13 US US11/250,267 patent/US7501448B2/en not_active Expired - Fee Related
- 2005-10-13 EP EP05812131A patent/EP1699765A1/en not_active Withdrawn
- 2005-10-13 KR KR1020087029493A patent/KR20080112424A/ko not_active Application Discontinuation
- 2005-10-13 JP JP2007518396A patent/JP2008503595A/ja active Pending
- 2005-10-13 CN CNA200580034694XA patent/CN101039917A/zh active Pending
-
2007
- 2007-03-20 IL IL182067A patent/IL182067A0/en unknown
-
2009
- 2009-01-12 US US12/319,834 patent/US20090124814A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04253966A (ja) * | 1990-07-23 | 1992-09-09 | Dr Karl Thomae Gmbh | ベンゾイミダゾール、これらの化合物を含む製薬組成物 |
JPH04346978A (ja) * | 1991-02-06 | 1992-12-02 | Dr Karl Thomae Gmbh | ベンズイミダゾール類及びこれらの化合物を含有する薬剤組成物 |
CN1344712A (zh) * | 2001-07-30 | 2002-04-17 | 中国科学院上海药物研究所 | 替米沙坦的合成新路线 |
WO2004087676A1 (de) * | 2003-03-31 | 2004-10-14 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von telmisartan |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011515374A (ja) * | 2008-03-20 | 2011-05-19 | レツク・フアーマシユーテイカルズ・デー・デー | アンギオテンシンiiアンタゴニストの合成における触媒カルボニル化 |
JP2011153080A (ja) * | 2010-01-26 | 2011-08-11 | Dnp Fine Chemicals Fukushima Co Ltd | テルミサルタンアルキルエステルの製造法 |
Also Published As
Publication number | Publication date |
---|---|
KR20080112424A (ko) | 2008-12-24 |
CN101039917A (zh) | 2007-09-19 |
US20060094883A1 (en) | 2006-05-04 |
US20090124814A1 (en) | 2009-05-14 |
KR20070061583A (ko) | 2007-06-13 |
CA2581723A1 (en) | 2006-04-27 |
IL182067A0 (en) | 2007-07-24 |
MX2007004426A (es) | 2007-06-14 |
US7501448B2 (en) | 2009-03-10 |
EP1699765A1 (en) | 2006-09-13 |
WO2006044648A1 (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008503595A (ja) | テルミサルタンの調製方法 | |
JP2017128605A (ja) | 抗ウイルス化合物の固体形態 | |
JP5160219B2 (ja) | テルミサルタンの製造方法 | |
TWI439457B (zh) | (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法 | |
JP2007526251A (ja) | エゼチミベ多形体 | |
CN110606860B (zh) | 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途 | |
JP2008539278A (ja) | 結晶性ロスバスタチンカルシウム | |
JP2014051517A (ja) | デフェラシロックス(icl670a)の多形形態 | |
KR20070072588A (ko) | 텔미사르탄 나트륨의 비정질형 및 다형 | |
EP1590343B1 (en) | Synthesis of 2-butyl-3-(2' -(1-trityl-1h-tetrazol-5-yl)biphen yl-4-yl)-1,3-diazaspiro-4,4 -nonene-4-one | |
CA2944210A1 (en) | Crystalline forms | |
US20090018182A1 (en) | Crystalline forms of atorvastatin | |
EP0308059B1 (en) | 1,2,3,4-tetrahydroisoquinoline antiarrhythmic agents | |
CN107540677B (zh) | 一种西格列汀衍生物或其药学上可接受的盐及其制备方法和应用 | |
KR101172472B1 (ko) | 4급 암모늄 화합물, 그 제조 방법, 뇌혈관 장애 치료제 및 심장 질환 치료제 | |
JP2008504369A (ja) | 1,24(s)−ジヒドロキシビタミンd2の結晶形態 | |
JPS61134372A (ja) | 新規なインドール誘導体 | |
JPWO2004101551A1 (ja) | ベンズイミダゾール誘導体の結晶及びその製造方法 | |
JP2005511787A (ja) | ナトリウム−水素交換1型阻害物質を調製する方法 | |
RU2242472C1 (ru) | Этаноляты n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина, способ их получения, фармацевтическая композиция на основе этих соединений и способ получения мезилатной соли n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина | |
AU2002222407A1 (en) | Ethanolates of sodium-hydrogen exchanger type-1 inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100601 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100608 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101102 |